A study arm from the phase 3 EMBARK trial evaluating XTANDI (enzalutamide) for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) with high-risk biochemical recurrence (BCR) has resulted in positive patient outcomes, according to Pfizer and Astellas Pharma. The phase 3, randomized, double-blind, placebo-controlled, multi-national EMBARK trial utilized 3 different study arms: enzalutamide plus leuprolide, placebo plus leuprolide, or enzalutamide monotherapy. A total of 1068 patients with nmCSPC who were considered high-risk BCR were enrolled and randomized to receive either enzalutamide 160 mg daily ...
Advertisement
Advertisement
Latest News
Dr. Goswami discusses the trials that are changing our understanding of resistance to ICIs in kidney and bladder cancer.
Patients with accRCC were assigned to receive either a conventional continuation strategy or a drug-free interval strategy.
Researchers used determined if an increase in ACM risk existed when sRT was delivered above a prespecified PSA level.
The TITAN-TCC trial examined the safety and efficacy of nivolumab induction with ipilimumab as an immunotherapeutic boost.
The new indication will improve access to imaging for approximately 32,000 candidates for radioligand therapy in the US.
In the final segment of a debate series, Brian Rini, MD, and Monty Pal, MD, debate RCC adjuvant therapeutic options.
The panel shares interesting clinical trial data in development, including CONTACT-03, TiNivo-2, and more.
The panel discusses triplet combinations in development for RCC.
The panel discusses the disappointing results of the COSMIC-313 trial.
The panel discusses exciting ongoing clinical trials, including 304, TiNivo-2, PDIGREE, and more.
The panel shares how they treat frontline papillary kidney cancer.
In the second segment of a debate series, Drs. Rini and Pal address kidney cancer clinical trials of interest.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, MScEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
David Ambinder, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
Expert Interviews
Dr. Goswami discusses the trials that are changing our understanding of resistance to ICIs in kidney and bladder cancer.
Mutahar Ahmed, MD, discusses the history and current applications of single-port robotic surgery in prostate cancer.
Dr. Msaouel provides an overview of the molecular characteristics and treatment for nccRCC, with a particular focus on RMC.
Rachelle Rodriguez, MS, APRN, AOCNP, highlights her role in helping Moffitt grow its APP presence within the GU onc program.
David Braun, MD, PhD, highlights the available later-line therapy options for RCC, how the therapies are sequenced, and more.
Rishabh Simhal, MD, discusses baseline fatigue and OS in patients with prostate cancer, as well as the FACIT-F questionnaire.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Conference Coverage
Live meeting highlights
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Video Insights
Clinical discussions with experts in the field
